UNSPSC 51352306: Orestrate

This classification denotes a therapeutic estrogen with the molecular formula C27H36O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G9VC23W7W0, chemically known as 1,3,5(10)-estratrien-3-ol, 17beta-(1-cyclohexenyloxy)-, propionate but generally known as orestrate, which bears US NIH Compound Identifier 167462. European Medicines Agency schedules Orestrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09459MIG. The term ORESTRATE is an International Non-Proprietary Name.

UNSPSC 51352306 Orestrate is a Commodity code under which state and local governments procure generic pharmaceutical products and over-the-counter medications supplied through established wholesale distribution channels. The work being solicited involves manufacturers providing comprehensive generic multi-source pharmaceuticals and OTC products with detailed product specifications including National Drug Codes (NDCs), SKUs, UPCs, generic descriptions, strength, dosage form, trade names, and packaging configurations. Vendors must certify compliance with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA), maintain contractual relationships with authorized wholesalers, and support electronic data interchange (EDI) capability. Products must be available in the marketplace and carry expiration dates of at least one year from manufacture with a minimum six-month shelf life. State and local government facilities, including departments of administration, health systems, and participating municipalities within cooperative purchasing consortiums, are the primary issuing bodies under this code.

Geographic activity centers on multistate cooperative purchasing vehicles. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal on January 20, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities, including Oregon. The solicitation number is S1070000015802, with proposals due March 26, 2026. Evaluation criteria weight price competitiveness at 75 percent, with the remaining 25 percent distributed across fixed pricing, administrative compliance, EDI capability, and agreement to a 3 percent administrative fee. Vendors must maintain commercial general liability insurance of $5,000,000 per occurrence and professional liability of $2,000,000. The contract term is two years for new vendors, with optional extensions at MMCAP's sole discretion, and performance penalties ranging from $200 to $1,500 per violation apply for late reporting, missed onboarding timelines, or improper class-of-trade denials.